title: Impact of genetic polymorphisms on clinical response to antithrombotics.
abstract: Antithrombotic therapy, including anticoagulants as well as antiplatelet drugs, is an important component in the treatment of cardiovascular disease. Variability in response to such medications, of which pharmacogenetic response is a major source, can decrease or enhance the benefits expected. This review is a comprehensive assessment of the literature published to date on the effects of genetic polymorphisms on the actions of a variety of antithrombotic medications, including warfarin, clopidogrel, prasugrel, and aspirin. Literature evaluating surrogate markers in addition to the impact of pharmacogenetics on clinical outcomes has been reviewed. The results of the studies are conflicting as to what degree pharmacogenetics will affect medication management in cardiovascular disease. Additional research is necessary to discover, characterize, and prospectively evaluate genetic and non-genetic factors that impact antithrombotic treatment in order to maximize the effectiveness and limit the harmful effects of these valuable agents.
authors.affiliation: Pharmacy Services, UK HealthCare, University of Kentucky, Lexington, Kentucky, USA; ; Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA;
authors.forename: Kena J
authors.initials: KJ
authors.lastname: Lanham
authors.forename: Julie H
authors.initials: JH
authors.lastname: Oestreich
authors.forename: Steven P
authors.initials: SP
authors.lastname: Dunn
authors.forename: Steven R
authors.initials: SR
authors.lastname: Steinhubl